- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The effect of hypoxia on PD-L1 expression in bladder cancer ; volume:21 ; number:1 ; day:25 ; month:11 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cancer ; 21, Heft 1 (25.11.2021), 1-11, 12.2021
- Urheber
-
Smith, Vicky
Mukherjee, Debayan
Lunj, Sapna
Choudhury, Ananya
Hoskin, Peter
West, Catharine
Illidge, Tim
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-09009-7
- URN
-
urn:nbn:de:101:1-2022020118013202855177
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Smith, Vicky
- Mukherjee, Debayan
- Lunj, Sapna
- Choudhury, Ananya
- Hoskin, Peter
- West, Catharine
- Illidge, Tim
- SpringerLink (Online service)
Ähnliche Objekte (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer
Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer